Verde Technologies Introduces Deterra® Drug Deactivation System

Verde Technologies Introduces Deterra® Drug Deactivation System

Company Partners with Businesses and Community Groups Working to Prevent Drug Misuse

The Centers for Disease Control and Prevention has classified prescription drug abuse as an epidemic, and the Office of National Drug Control Policy’s Prescription Drug Abuse Plan includes “proper medication disposal” as one of four major action areas to reduce prescription drug abuse. From the Community Anti-Drug Coalitions of America’s (CADCA) National Leadership Forum, Verde Technologies announced today a new name and partnership program in the fight against prescription drug abuse and misuse: Deterra Drug Deactivation System.

Originally introduced as Medsaway, the Deterra System utilizes patented MAT12TM Molecular Adsorption Technology to deactivate unwanted, unneeded narcotics, antibiotics, transdermal patches and other prescription drugs, rendering them ineffective for misuse and safe for the environment. The Deterra System features a pouch containing MAT12, a proprietary activated carbon that bonds to pharmaceutical compounds when water is added, rendering drugs ineffective and safe for disposal quickly in any setting – home, clinic or hospital.

Deterra has a 98.1 percent success rate in deactivating prescription drugs, according to a research study supported by the National Institute on Drug Abuse (NIDA). Designed to be a cost-effective and easy-to-use drug abuse deterrent, Deterra is also environmentally friendly as it renders chemical compounds safe for landfills. It also provides an excellent alternative to take back incineration programs and potentially reduces watershed contamination. Deterra also promotes social responsibility as it closes the product lifecycle for pharmaceutical companies and health care providers, and offers the opportunity to reduce misuse-related medical emergencies and demonstrates commitment to personal and public health.

New Partnership Program Helps Companies and Groups Working to Prevent Drug Abuse and Misuse

The Federal Drug Administration (FDA) is actively working with drug manufacturers on abuse deterrent formulations. Formulations are one way to prevent abuse and misuse, but effective ways to deactivate and dispose of drugs are equally as important. To help organizations demonstrate social responsibility as regulations around the issue take shape, Verde also announces a new Deterra partnership program available for companies and advocacy groups, such as manufacturers, payers and health insurance companies, pharmacies, hospitals and surgery centers, community organizations and police departments. For organizations committed to supporting and implementing solutions to reduce ongoing issues of prescription drug abuse and misuse, the Deterra partnership program provides a cost-effective, environmentally and socially responsible way to quell the urgent issue through distribution of the Deterra System pouches at physician offices, pharmacies, hospitals and community locations to safely dispose of unused and unwanted medications.

“Verde is committed to reducing the growing problems of abuse and misuse of drugs plaguing the United States, and our new Deterra System and partnership program provides a proven, universal solution that is socially responsible, cost-
effective, easy to use and environmentally friendly,” said Christine Horton, Verde Technologies vice president of sales and marketing. “Our partnership program extends the opportunity to the pharmaceutical and health care industries to change behavior and make a real difference in reducing prescription drug misuse and abuse.”

The Deterra System is available in several sizes and formats, providing options for individual and institutional use. Deterra-SP is a single pouch design with a recommended capacity of 15 pills, 2 ounces of liquid or two transdermal patches per pouch. Deterra-MP deactivates up to 45 pills, 6 ounces of liquid or six patches; Deterra-LP has a capacity of 90 pills, 12 ounces of liquid or 12 patches; and Deterra Pro contains three Deterra-LP pouches. Deterra XL is available for hospitals and clinics, providing a larger one-gallon size with a total capacity of 450 pills, 60 ounces of liquid or 60 patches. Deterra Contra-Patch contains 25 pouches, each with a capacity for one patch. The Deterra System is available to partners, with the smallest size priced significantly under $1 each.

For more information on the Deterra System or partnership program, visit, or contact